Merck’s CHOZN® Expression System Selected for Bi-specific Antibody Development by SystImmune

• Accelerates development timelines with faster, easier selection and scale up of clones
• Delivers higher titers of recombinant proteins

Darmstadt, Germany, May 16, 2017 — Merck today announced that its CHOZN® expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic.

The CHOZN® expression system is designed to deliver manufacturing-ready robust and stable producing clones with a workflow that minimizes the resources needed to complete a cell line development project. As a result, users are able to quickly evaluate more molecules in their pipeline.

“When compared with alternate expression systems, our CHOZN® system offers a turnkey solution that consistently delivers shortened development timelines,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.

Merck’s CHOZN® expression system is based on a GS -/- Chinese hamster ovary (CHO) cell line.

“With only two scientists in our cell science department, we were able to generate more than 10 stable cell lines using this platform in a single year,” said Camilla Wang, Scientist, SystImmune. “The CHOZN® platform outperformed other systems in many ways. It is easy to use, requires less time to generate final single cell clones, and most of all, the expression level is consistently higher compared to the other approaches.”

Along with the CHOZN® cells, Merck provides an expression vector, extensive user protocols, a comprehensive cell line history document and paired cGMP media and feeds. Services are offered for cell line development in the CHOZN® expression system. Merck also offers gene engineering services using its CompoZr™ zinc finger nuclease technology to engineer CHO cell lines with characteristics attractive to biopharmaceutical developers and manufacturers, including resistance to Centinel™ technology.

メルクについて
Merck（メルク）はヘルスケア、ライフサイエンス、パフォーマンスマテリアルズの分野における世界有数のサイエンスとテクノロジー企業です。がんや多発性硬化症のためのバイオ医薬品を用いた治療法から、科学研究と生産に関する最先端システム、スマートフォンや液晶テレビ向けの液晶材料にいたるまで、約53,000人の従業員が人々の暮らしをより良くする技術の一層の進歩を目指しています。2017年は66カ国で153億ユーロの売上高を計上しました。

メルクは1668年に創業された世界で最も歴史の長い医薬・化学品会社で、 創業家が今でも、上場企業が率いるメルクグループの株式の過半数を所有しています。メルクの名称およびブランドのグローバルな権利は、メルクが保有しています。唯一の例外は米国とカナダで、両国ではEMDセローノ、ミリポアシグマ、EMDパフォーマンスマテリアルズとして事業を行っています。